Digest Network Come funziona
Network
/
Società
LE
Non verificato

LEO Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

41 comunicati stampa

Guarda tutti i comunicati
16/12/2025
Mercato del lavoro
Salute
Sanità
Scienza
Medicina - Varie
Farmaceutica
LEO Pharma Appoints Marika Murto to Lead Global Product Strategy
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
15/12/2025
Industria
Salute
Sanità
Scienza
Medicina - Varie
Farmaceutica
LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
17/11/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
06/11/2025
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
LEO Pharma Delivers 8% Revenue Growth at CER in 9M 2025 and Updates Full-Year Outlook
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
05/11/2025
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
LEO Pharma Announces NICE Recommendation of Reimbursement in England and Wales
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
03/11/2025
Sanità
Salute
Medicina - Varie
Mercato del lavoro
LEO Pharma Strengthens Leadership in Medical Dermatology with the Appointment of Sophie Lamle as Chief Development Officer
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
21/10/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
01/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
LEO Pharma Closes Deal for Spevigo®
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
19/09/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0
17/09/2025
Eventi
Industria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris
Fonte
LEO Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0